Carlos M. De Castro, MD, highlights the phase III Apply-PNH study presented at ASH 2022.
ASH 2022 Post Conference Perspectives: Innovations in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dr De Castro provides an overview of IV versus oral therapies for patients with PNH.
Biosimilar products may be utilized as treatment options in PNH.
Dr De Castro explores considerations surrounding cost in treatment of PNH.
In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment.
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
2
Value-Based Care Interventions and Management of CKD Progression
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
CDC Reports Largest Pediatric Influenza-Associated Encephalopathy Case Series in 2024-2025 Season
5
